Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies

By afschroeder • June 8, 2025

Ouyang Q, Rodon J, Liang Y, Wu X, Li Q, Song L, Yan M, Tong Z, Liu Y, Wainberg ZA, Wang Y, Geng C, Ulahannan SV, Yu G, Sharma MR, Wang X, Wang JS, Spira A, Zhao W, Sanborn RE, Cheng Y, Wang X, Liu G, Li Y, Ge J, Chartash E, Akala OO, Yin Y. Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies. J Hematol Oncol. 2025 Jun 6;18(1):61. doi: 10.1186/s13045-025-01705-2. PMID: 40481574; PMCID: PMC12142944.

Tags: Antibody–drug conjugate, Hematology/Oncology, HR+/HER2− breast cancer, Publications, Sac-TMT, triple-negative breast cancer

Related Posts

Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer

Arbour KC, Punekar S, Luo J, Johnson M, Spira A, Herzberg B, Starodub A, Sommerhalder D, Hecht JR, Garrido-Laguna I, Barve M, Ou SI, Kar[...]

Associations of neighborhood deprivation with breast cancer tumor genomics, targeted treatment use, and survival

Podany EL, Foffano L, Gerratana L, Medford AJ, Heater NK, Nicolò E, Tapiavala S, Pontolillo L, Putur A, Jaber DA, Clifton K, Katakam N, Addison[...]

L-Glutamine in combination with first-line gemcitabine and nab-paclitaxel in advanced pancreatic ductal adenocarcinoma: an open-label, single-arm, phase 1 GlutaPanc trial

Gong J, Muranaka H, Choi SY, Tighiouart M, Bhute S, Aja ER, Jacobs JP, Stotland A, Van Eyk J, Elmadbouh OHM, Edderkaoui M, Tanaka S,[...]